Victory Capital Management Inc. Increases Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Victory Capital Management Inc. increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,917,551 shares of the medical equipment provider’s stock after buying an additional 24,358 shares during the quarter. Victory Capital Management Inc. owned 2.18% of Hologic worth $354,506,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. General Partner Inc. purchased a new stake in shares of Hologic in the fourth quarter valued at about $26,000. Groupama Asset Managment increased its stake in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC lifted its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. boosted its stake in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the last quarter. Finally, Smartleaf Asset Management LLC increased its position in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Performance

Hologic stock opened at $62.30 on Wednesday. The stock has a market cap of $13.98 billion, a P/E ratio of 19.65, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a fifty-two week low of $62.28 and a fifty-two week high of $84.67. The firm’s fifty day moving average price is $68.77 and its 200-day moving average price is $75.64.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on HOLX. Citigroup cut their price objective on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday. Wolfe Research began coverage on shares of Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Finally, William Blair restated an “outperform” rating on shares of Hologic in a research note on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Hold” and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.